"Onco360 is grateful for the opportunity to partner with the team at Astellas and become a specialty pharmacy provider for ...

CD BioSciences, a US-based biotechnology company focusing on the development of imaging technologies, is proud to introduce ...

Screening for pancreatic cancer is recommended for individuals with the above risk factors around 50 years of age or 10 years ...

Pancreatic cancer, specifically pancreatic adenocarcinoma, remains one of the most aggressive and deadliest cancers worldwide ...

Q3 2024 Earnings Call Transcript November 25, 2024 Operator: Ladies and gentlemen, thank you for standing by. Welcome to the ...

Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with ...

Recent research has shown that, in comparison to symptom-based follow-up, routine imaging in follow-up after pancreatic ...

Mutant KRAS is implicated in pancreatic, lung and colorectal cancers. G12V and G12D mutations in KRAS affect ~90% of ...

Combination treatment with entinostat and nivolumab results in durable responses in a small subset of patients with advanced ...

Our objectives are (1) to describe the prevalence of actionable genomic alterations in Brazilian patients diagnosed with advanced lung adenocarcinoma, (2) to define the proportion of samples eligible ...

Investment analysts at HC Wainwright lifted their FY2024 earnings estimates for Lisata Therapeutics in a research report ...